Intraperitoneal therapy for peritoneal cancer

摘要: Cancers originating from organs in the peritoneal cavity (e.g., ovarian, pancreatic, colorectal, gastric and liver) account for approximately 250,000 new cancer cases annually USA. Peritoneal metastases are common owing to locoregional spread distant of extraperitoneal cancers. A logical treatment is intraperitoneal therapy, as multiple studies have shown significant targeting advantage this treatment, including survival benefits stage III, surgically debulked ovarian patients. However, clinical use therapy has been limited, part, by toxicity, indwelling catheters or high drug exposure, inadequate penetration into bulky tumors (>1 cm) lack products specifically designed approved treatments. This article provides an overview on background metastasis, research pharmacokinetic basis delivery our development drug-loaded tumor-penetrating microparticles.